Prothena Corp Public (PRTA) Share-based Compensation (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Share-based Compensation of $6.9 million for Q1 2026, down 36.84% year-over-year from $10.9 million in Q1 2025, and down 2.25% quarter-over-quarter from $7.1 million in Q4 2025.
Prothena Corp Public (PRTA) Share-based Compensation (2012 - 2026) Analysis & Trends
Prothena Corp Public's Share-based Compensation history runs 15 years deep, the most recent figure standing at $6.9 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 36.84% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $33.6 million (up 2861.38% YoY), while the FY2025 annual figure was $37.6 million, up 17245.62% from the prior year.
- Share-based Compensation for Q1 2026 stood at $6.9 million, down from $7.1 million in the prior quarter.
- The five-year high for Share-based Compensation was $31.2 million in Q4 2022, with the low at -$35.2 million in Q4 2024.
- The 5-year median for Share-based Compensation is $10.1 million (2023), against an average of $8.3 million.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation jumped 233.79% in 2022, then slumped 417.93% in 2024.
- Prothena Corp Public's Share-based Compensation stood at $31.2 million in 2022, then slumped by 64.45% to $11.1 million in 2023, then plunged by 417.93% to -$35.2 million in 2024, then surged by 120.08% to $7.1 million in 2025, then declined by 2.25% to $6.9 million in 2026.
- Business Quant data shows PRTA's Share-based Compensation at $6.9 million in Q1 2026, $7.1 million in Q4 2025, and $7.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - | 7.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.88 Mn |
| Jun 30, 2026 | 7.88 Mn |
| Mar 31, 2026 | 6.92 Mn |
| Mar 31, 2026 | 6.92 Mn |
| Dec 31, 2025 | 7.07 Mn |
| Dec 31, 2025 | 7.07 Mn |
| Sep 30, 2025 | 7.20 Mn |
| Sep 30, 2025 | 7.20 Mn |
| Jun 30, 2025 | 12.42 Mn |
| Jun 30, 2025 | 12.42 Mn |
| Mar 31, 2025 | 10.95 Mn |
| Mar 31, 2025 | 10.95 Mn |
| Dec 31, 2024 | -35.23 Mn |
| Dec 31, 2024 | -35.23 Mn |
| Sep 30, 2024 | 11.02 Mn |
| Sep 30, 2024 | 11.02 Mn |
| Jun 30, 2024 | 12.04 Mn |
| Jun 30, 2024 | 12.04 Mn |
| Mar 31, 2024 | 12.38 Mn |
| Mar 31, 2024 | 12.38 Mn |